LABORATORY SCIENCES. Treatment of Experimental Bacterial Keratitis With Topical Trovafloxacin
|
|
- Phoebe Mathews
- 6 years ago
- Views:
Transcription
1 LABORATORY SCIENCES Treatment of Experimental Bacterial Keratitis With Topical Trovafloxacin Irina S. Barequet, MD; Paul Denton, BS; Gerard J. Osterhout, MS; Suhas Tuli, MD; Terrence P. O Brien, MD Objective: To investigate the therapeutic role of trovafloxacin mesylate, a newer-generation fluoroquinolone with an expanded spectrum of activity, in the treatment of experimental bacterial keratitis. Methods: Susceptibility studies were performed on various strains of ocular isolates to determine the minimum inhibitory concentration (MIC) of trovafloxacin compared with ciprofloxacin and ofloxacin, using the E-test method. Pharmacokinetic studies were performed by a single topical administration of trovafloxacin to rabbit eyes with either an intact or denuded corneal epithelium. Aqueous humor, vitreous, and corneal concentrations of trovafloxacin were determined at different time points. Experimental bacterial keratitis studies were performed in rabbit eyes. Three identical studies were conducted using Staphylococcus aureus, Streptococcus pneumoniae, orpseudomonas aeruginosa. Therapy groups included 0.5% trovafloxacin, 0.3% ciprofloxacin, 0.3% ofloxacin, and isotonic sodium chloride solution. After 12 hours of drops administration, corneas were excised, homogenized, and serially plated. The main outcome measure was quantitative bacteriologic analysis for residual colony-forming units. Results: In vitro susceptibility study findings indicated that the MIC of trovafloxacin was significantly lower than the MIC of ciprofloxacin and ofloxacin for S aureus, S pneumoniae, and Haemophilus influenzae, lower than the MIC of ciprofloxacin and ofloxacin for Staphylococcus epidermidis, and intermediate between ciprofloxacin and ofloxacin for P aeruginosa. Pharmacokinetic studies showed a significant concentration of trovafloxacin in the treated corneas, especially in eyes with a denuded epithelium. All serum samples had undetectable trovafloxacin concentrations. Experimental keratitis studies showed a statistically significant decrease of colony-forming units in trovafloxacin-treated eyes in the S aureus model and a similar decrease in the S pneumoniae and P aeruginosa models. Conclusions: Topical 0.5% trovafloxacin proved to be an effective ocular medication for the therapy of grampositive and gram-negative keratitis. Clinical Relevance: Trovafloxacin may provide an excellent therapeutic alternative in bacterial keratitis. Arch Ophthalmol. 2004;122:65-69 From the Ocular Microbiology Laboratory, The Wilmer Ophthalmological Institute, The Johns Hopkins University School of Medicine, Baltimore, Md (Drs Barequet, Tuli, and O Brien and Messrs Denton and Osterhout); and Goldschleger Eye Institute, Sheba Medical Center, Tel Aviv University Sackler School of Medicine, Tel Hashomer, Israel (Dr Barequet). The authors have no relevant financial interest in this article. MICROBIAL KERATITIS continues to be a common, potentially sightthreatening ocular infection. 1,2 Fluoroquinolones are increasingly selected as initial, broad-spectrum agents for the topical therapy of bacterial keratitis. 3 The use of ofloxacin and ciprofloxacin, as single agents, was shown in clinical trials to be comparable to a combination of fortified antibiotics in the treatment of acute bacterial keratitis. 4,5 However, these 2 quinolones, which currently are often used, have limited in vitro activity against some grampositive organisms and various strains of Pseudomonas aeruginosa. 6,7 Trovafloxacin mesylate, 7-(3- azabicyclo[3,1,0]hexyl)-naphthyridone, is a newer-generation synthetic fluoroquinolone currently available for oral and intravenous administration. Trovafloxacin has broad spectrum antibacterial activity against gram-negative, gram-positive, and anaerobic bacteria. In vitro and in vivo studies 8-13 in systemic diseases have demonstrated a greater activity against clinically important gram-positive organisms (most notably streptococci), while maintaining activity against gram-negative organisms, when compared with ciprofloxacin and ofloxacin. The purpose of this study is to determine the microbiological efficacy of topical trovafloxacin for potential use in therapy of experimental bacterial keratitis. After performing susceptibility and pharmacokinetic studies, we studied the microbiological effect of topical trovafloxacin on bacterial keratitis caused by either gram-positive organisms, such as Staphylococcus aureus and Streptococcus 65
2 pneumoniae, or a gram-negative organism (P aeruginosa) and compared its efficacy with that of ciprofloxacin and ofloxacin. METHODS BACTERIAL STRAINS Bacterial strains used in this study were clinical ocular isolates collected from corneal specimens at the Wilmer Ophthalmological Institute, Baltimore, Md. ANTIMICROBIAL SUSCEPTIBILITY STUDIES Minimum inhibitory concentrations (MICs) of trovafloxacin, ciprofloxacin, and ofloxacin were determined for various ocular isolates of S aureus, S pneumoniae, Staphylococcus epidermidis, P aeruginosa, and Haemophilus influenzae. The E-test method was used for determining the MIC for each strain. The bacterial suspension was prepared by collecting the clinical isolates from a blood agar plate. The isolate sample was adjusted with 0.9% nonbacteriostatic isotonic sodium chloride solution to achieve the same density as a 0.5 McFarland standard ( colony-forming units/ml). The appropriate E-test strip was placed on a Mueller-Hinton II agar plate (BBL, Cockeysville, Md) inoculated with the suspension of bacteria. The plates were incubated for 16 to 24 hours at 37 C, and the MIC was read from the scale on the side of the strip at the point where the ellipse of growth inhibition intercepted the strip. All the tests were performed in duplicate. PHARMACOKINETIC STUDIES The pharmacokinetic studies were performed on rabbit eyes. Twelve rabbits were used for this study. Epithelial removal (to promote antibiotic entry and to simulate human ulcerative keratitis) was evaluated. In each rabbit, one eye underwent removal of the central (7.5 mm) corneal epithelium, and in the fellow eye the epithelium remained intact. A single drop of trovafloxacin was applied to both eyes. Rabbits were humanely killed at 15, 30, 60, 120, and 240 minutes (at each time point, 3 rabbits were euthanized), and samples were obtained immediately thereafter from aqueous humor, vitreous, and the central cornea (7.5 mm). The tissue concentration of trovafloxacin was determined using a high-performance liquid chromatography assay. 14 BACTERIAL KERATITIS STUDIES In these studies, 72 (24 in each experiment) New Zealand white rabbits, weighing 2.0 to 2.25 kg, were used in accordance with the guidelines for animal experimentation established by the Association of Research in Vision and Ophthalmology (Rockville, Md); approval from the appropriate institutional review board was obtained for the study, and the institutional guidelines regarding animal experimentation were followed. All rabbits were sedated and anesthetized with intramuscular injection of ketamine hydrochloride (60 mg/kg) and xylazine hydrochloride (12 mg/kg) and topical 0.5% proparacaine hydrochloride before having only one eye of each animal injected with bacteria. To produce keratitis, 10 3 colony-forming units (0.1 ml) of clinical bacterial isolates in logarithmic growth phase were injected into the corneal stroma in one eye. The injection was performed with a 30-gauge needle into the stroma in the central part of the cornea under microscopic guidance. The first experiment was performed with 24 rabbits, using a clinical isolate of a methicillin-sensitive S aureus with a predetermined MIC50 (inhibits 50% of strains) of 0.5 µg/ml for ciprofloxacin. The other 2 experiments were performed in an identical fashion by inoculating either S pneumoniae or P aeruginosa. Twelve hours after the injection, the rabbits were randomized to 4 treatment groups, with 6 rabbits in each group: (1) ciprofloxacin, 3 mg/ml (Ciloxan 0.3%; Alcon Laboratories, Fort Worth, Tex); (2) ofloxacin, 3 mg/ml (Ocuflox 0.3%; Allergan, Irvine, Calif); (3) trovafloxacin mesylate, 5 mg/ml (Trovan- IV; Pfizer, New York, NY); and (4) preservative-free 0.9% nonbacteriostatic isotonic sodium chloride solution for intravenous use (control). Trovafloxacin eyedrops were prepared using the intravenous solution that was transferred into a dropper bottle under a sterile hood. The eyedrops were administered every hour for 12 hours. One hour after the last dose of eyedrops, the rabbits were systemically anesthetized and then humanely killed by intracardiac injection of pentobarbital sodium (Beuthanasia-D Special; Schering-Plough Animal Health Corp, Kenilworth, NJ). The rabbits corneas were excised using a sterile, disposable, 7.5-mm corneal trephine and irrigated with 3 ml of phosphatebuffered saline to eliminate any residual antibiotic or debris on the surface of the corneas. The corneal buttons were immediately homogenized and then serially diluted before plating in duplicate on blood agar for S aureus and S pneumoniae and on Mueller-Hinton II agar for P aeruginosa. The specimens were incubated at 35 C for 24 hours before quantitative bacteriologic analysis. RESULTS ANTIMICROBIAL SUSCEPTIBILITY STUDIES The MICs for the various ocular strains are given in Table 1. The MIC for P aeruginosa strains was significantly lower for ciprofloxacin compared with trovafloxacin (P=.008) and ofloxacin (P=.007) and significantly lower for trovafloxacin compared with ofloxacin (P=.007). The MIC for S aureus strains was significantly lower for trovafloxacin compared with ciprofloxacin (P.001) and ofloxacin (P.001), and no significant difference was found between the MIC for ciprofloxacin and ofloxacin (P=.10). The MIC for H influenzae strains was significantly lower for trovafloxacin (P=.005) and ciprofloxacin (P=.005) compared with ofloxacin. No significant difference was found between trovafloxacin and ciprofloxacin (P=.44). The MIC for S epidermidis was lower for trovafloxacin than ciprofloxacin; however, this was not statistically conclusive (P=.07). The MIC for S pneumonia strains was significantly lower for trovafloxacin (P=.006) and ciprofloxacin (P=.006) compared with ofloxacin. PHARMACOKINETIC STUDIES After the single trovafloxacin drop application, a substantial penetration was found in the corneas at all time points (Table 2). Mean (SD) trovafloxacin levels were higher in eyes with denuded epithelium (25.9 [22.1] µg/g) compared with intact epithelium (3.7 [2.2] µg/g). The aqueous levels were higher in eyes with denuded epithelium (2.5 [1.4] µg/ml) compared with intact epithelium (0.3 [0.1] µg/ml). The vitreous concentrations after a single topical application were low in most of the 66
3 eyes. All serum samples for all the time points had undetectable trovafloxacin concentrations. BACTERIAL KERATITIS STUDIES The bacterial counts for the 3 studies are given in Table 3. The S aureus keratitis study showed a statistically significant decrease in bacterial counts in the groups treated with trovafloxacin compared with the ciprofloxacin and ofloxacin treatment groups (P=.002). The S pneumoniae study showed a significant decrease in bacterial counts in the antibiotic-treated groups compared with the controls (P=.002) and a significant decrease in bacterial counts in the trovafloxacin groups compared with ciprofloxacin but not ofloxacin. The P aeruginosa study showed a significant decrease in all antibiotic-treated groups compared with the control group (P.001). COMMENT Until recently, the fluoroquinolones were primarily agents with excellent activity against gram-negative bacilli but with questionable activity against some important grampositive pathogens. Newer agents under development have an expanded profile of antibacterial activity against grampositive pathogens, including staphylococci, streptococci, enterococci, and anaerobic isolates. The fluoroquinolone evolutionary tree has 2 main branches. The first branch is the naphthyridine series, which have a nitrogen atom at the C-8 position (eg, nalidixic acid, enoxacin, tosufloxacin, trovafloxacin); all others are fluoroquinolone agents, with the C-7 position being the most adaptable site for chemical substitution. A major clinical challenge has been the worldwide emergence and spread of antimicrobial resistance, especially among gram-positive isolates, such as pneumococci. There is recent information on the mechanism of action of fluoroquinolone and how resistance develops. From this, it seems that the most efficient use of these fluoroquinolone compounds is to use a highly active agent with a favorable pharmacodynamic profile for the shortest treatment duration consistent with cure. Trovafloxacin is a newer-generation, expandedspectrum fluoroquinolone, which was shown in our study to have in vitro potency, favorable pharmacokinetics, and in vivo efficacy, suggesting a potential role in the therapy of bacterial keratitis. The use of topical fluorinated quinolones has become a frequent, initial, single-agent therapy for bacterial keratitis. 4,5 The mechanism of action of the quinolones is via inhibition of the type II topoisomerase DNA gyrase, an essential bacterial enzyme that alters the topology of double-stranded DNA within the cell. Inhibition of this activity by fluoroquinolones is associated with rapid killing of the bacterial cell. 15 The important advantages in the systemic use of trovafloxacin are the pharmacokinetic properties and its expanded antibacterial spectrum, especially against grampositive organisms, including Streptococcus species. Our results showed that trovafloxacin not only is effective against P aeruginosa, similar to other experimental keratitis studies, 16,17 but also is superior as far as activity against gram-positive bacteria Table 1. Comparative In Vitro Activity of Trovafloxacin Against Ocular Strains of Various Microorganisms MIC, µg/ml Trovafloxacin Bacteria and Strain Mesylate Ciprofloxacin Ofloxacin Pseudomonas aeruginosa OJ J SN P N J OJ J Mean MIC Staphylococcus aureus 4N J OJ J P ON OJ E J OP N Mean MIC Streptococcus pneumoniae B Mean MIC Haemophilus influenzae Mean MIC Staphylococcus epidermidis Mean MIC Abbreviation: MIC, minimum inhibitory concentration. The current clinical use of trovafloxacin so far has been systemic, intravenous, intramuscular, or oral. The intravenous formulation of trovafloxacin is the prodrug alatrofloxacin mesylate, which has little intrinsic anti- 67
4 Table 2. Tissue Concentrations of Trovafloxacin Mesylate at Different Time Points After Application of a Single Drop of 0.5% Trovafloxacin* Corneal Button, µg/g Aqueous, µg/ml Vitreous, µg/ml Time Point, min Intact Denuded Intact Denuded Intact Denuded Serum, µg/ml Mean (SD) 3.7 (2.2) 25.9 (22.1) 0.3 (0.1) 2.5 (1.4) (0.1) 0.1 *Intact and denuded refer to the corneal epithelium. Table 3. Bacterial Counts for Each Antibiotic Treatment Group* Bacterial Count, CFU 10 4 /L Bacteria Trovafloxacin Mesylate Ciprofloxacin Ofloxacin Control Staphylococcus aureus Mean (SD) 1.45 (2.11) (40.95) (90.72) (655.01) Median % Quartile % Quartile Streptococcus pneumoniae Mean (SD) 1.64 (3.56) (57.4) 1.57 (1.26) (333.79) Median % Quartile % Quartile Pseudomonas aeruginosa Mean (SD) (137.17) Median % Quartile % Quartile Abbreviation: CFU, colony-forming units. *Corneas were excised 25 hours after the induction of keratitis (1 hour after the completion of the 12-hour therapy administration). bacterial activity in vitro but demonstrates good activity in vivo as a result of undergoing rapid hydrolysis and is rapidly converted to trovafloxacin after intravenous administration. We used the intravenous formulation for preparation of the eyedrops, and this demonstrated a good antibacterial activity in topical use for the keratitis model. In vitro activity of trovafloxacin has been shown to be superior to both ciprofloxacin and ofloxacin against both the penicillin-susceptible and penicillin-resistant pneumococci. 23,24 In our study the in vitro antibacterial activity of trovafloxacin against ocular isolates has been demonstrated by using the E-test, a modification of a disc diffusion susceptibility testing. 25 Pascual et al 26 showed that trovafloxacin penetrates into phagocytic and nonphagocytic cells, reaching intracellular concentrations several times greater than the extracellular ones, whereas it remained active intracellularly in human polymorphonuclear leukocytes; this fact may enhance the in vivo antibacterial activity. Lately, the systemic use of trovafloxacin was restricted to lifeor limb-threatening conditions due to several reports of hepatic toxicity after systemic use of the drug. 27,28 With topical ocular use, the expected systemic levels are extremely low, if detectable at all; moreover, the restricted systemic use may offer an advantage with the topical use due to a lesser chance of emergence of resistance. In conclusion, the high in vitro efficacy against ocular isolates along with the high ocular tissue penetration and nondetectable systemic levels and in vivo efficacy indicate that trovafloxacin may have an important clinical role in the topical treatment of bacterial keratitis, including streptococcal species. Submitted for publication August 1, 2003; final revision received August 12, 2003; accepted August 21, Corresponding author and reprints: Terrence P. O Brien, MD, Ocular Microbiology Laboratory, The Wilmer Ophthalmological Institute, Woods 255, 600 N Wolfe St, Baltimore, MD ( tobrien@jhmi.edu). REFERENCES 1. Lam DS, Houang E, Fan DS, Lyon D, Seal D, Wong E. Incidence and risk factors for microbial keratitis in Hong Kong: comparison with Europe and North America. Eye. 2002;16: Scott IU, Flynn HW Jr, Feuer W, et al. Endophthalmitis associated with microbial keratitis. Ophthalmology. 1996;103:
5 3. McDonnell PJ, Nobe J, Gauderman WJ, Lee P, Aiello A, Trousdale M. Community care of corneal ulcers. Am J Ophthalmol. 1992;114: O Brien TP, Maguire MG, Fink NE, Alfonso E, McDonnell P. Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis: report from the Bacterial Keratitis Study Research Group. Arch Ophthalmol. 1995;113: Hyndiuk RA, Eiferman RA, Caldwell DR, et al, Ciprofloxacin Bacterial Keratitis Study Group. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ophthalmology. 1996; 103: Chaudhry NA, Flynn HW Jr, Murray TG, Tabandeh H, Mello MO Jr, Miller D. Emerging ciprofloxacin-resistant Pseudomonas aeruginosa. Am J Ophthalmol. 1999; 128: Kunimoto DY, Sharma S, Garg P, Rao GN. In vitro susceptibility of bacterial keratitis pathogens to ciprofloxacin: emerging resistance. Ophthalmology. 1999;106: Gooding BB, Jones RN. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrob Agents Chemother. 1993;37: Eliopoulos GM, Klimm K, Eliopoulos CT, Ferraro MJ, Moellering RC Jr. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of grampositive bacteria. Antimicrob Agents Chemother. 1993;37: Felmingham D, Robbins MJ, Ingley K, et al. In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates. J Antimicrob Chemother. 1997;39(suppl): Dembry LM, Farrel PA, Orcutt LA, Gerrity LA, Andriole VT. In-vitro activity of trovafloxacin against sensitive and resistant aerobic bacteria using the standard microdilution broth method and E-test. J Antimicrob Chemother. 1997;39(suppl): Hoogkamp-Korstanje JA. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against grampositive and gram-negative pathogens from respiratory tract infections. J Antimicrob Chemother. 1997;40: Cunha BA, Qadri SM, Ueno Y, Walters EA, Domenico P. Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates. J Antimicrob Chemother. 1997;39(suppl): Teng R, Tensfeldt TG, Liston TE, Foulds G. Determination of trovafloxacin, a new quinolone antibiotic, in biological samples by reversed-phase highperformance liquid chromatography. J Chromatogr B Biomed Appl. 1996;675: Brighty KE, Gootz TD. The chemistry and biological profile of trovafloxacin. JAntimicrob Chemother. 1997;39(suppl): Reidy JJ, Hobden JA, Hill JM, Forman K, O Callaghan RJ. The efficacy of topical ciprofloxacin and norfloxacin in the treatment of experimental Pseudomonas keratitis. Cornea. 1991;10: Guzek JP, Chacko D, Kettering JD, Wessels IF, Aprecio RM. Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of experimental Pseudomonas aeruginosa keratitis. Cornea. 1994;13: Callegan MC, Hill JM, Insler MS, Hobden JA, O Callaghan RJ. Methicillinresistant Staphylococcus aureus keratitis in the rabbit: therapy with ciprofloxacin, vancomycin and cefazolin. Curr Eye Res. 1992;11: Callegan MC, Hobden JA, Hill JM, Insler MS, O Callaghan RJ. Topical antibiotic therapy for the treatment of experimental Staphylococcus aureus keratitis. Invest Ophthalmol Vis Sci. 1992;33: Callegan MC, Hobden JA, Hill JM, Insler MS, O Callaghan RJ. Topical antibiotic therapy for the treatment of experimental Staphylococcus aureus keratitis. Invest Ophthalmol Vis Sci. 1992;33: Lauffenburger MD, Cohen KL. Topical ciprofloxacin versus topical fortified antibiotics in rabbit models of Staphylococcus and Pseudomonas keratitis. Cornea. 1993;12: Guzek JP, Cline DJ, Row PK, et al. Rabbit Streptococcus pneumoniae keratitis model and topical therapy. Invest Ophthalmol Vis Sci. 1998;39: Child J, Andrews J, Boswell F, Brenwald N, Wise R. In-vitro activity of CP- 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. J Antimicrob Chemother. 1995;35: Klugman KP, Gootz TD. In-vitro and in-vivo activity of trovafloxacin against Streptococcus pneumoniae. J Antimicrob Chemother. 1997;39(suppl): Brown DF, Brown L. Evaluation of the E test, a novel method of quantifying antimicrobial activity. J Antimicrob Chemother. 1991;27: Pascual A, Garcia I, Ballesta S, Perea EJ. Uptake and intracellular activity of trovafloxacin in human phagocytes and tissue-cultured epithelial cells. Antimicrob Agents Chemother. 1997;41: Lucena MI, Andrade RJ, Rodrigo L, et al. Trovafloxacin-induced acute hepatitis. Clin Infect Dis. 2000;30: Chen HJ, Bloch KJ, Maclean JA. Acute eosinophilic hepatitis from trovafloxacin. N Engl J Med. 2000;342:
PDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/26062
More informationagainst Clinical Isolates of Gram-Positive Bacteria
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 366-370 Vol. 37, No. 0066-0/93/00366-05$0.00/0 Copyright 993, American Society for Microbiology In Vitro Activity of CP-99,9, a New Fluoroquinolone,
More informationIn Vitro Antimicrobial Activity of CP-99,219, a Novel Azabicyclo-Naphthyridone
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 39-353 0066-0/93/0039-05$0.00/0 Copyright 993, American Society for Microbiology Vol. 37, No. In Vitro Antimicrobial Activity of, a Novel Azabicyclo-Naphthyridone
More informationCiprofloxacin Versus Tobramycin for the Treatment of Staphylococcal Keratitis
Ciprofloxacin Versus Tobramycin for the Treatment of Staphylococcal Keratitis Michelle C. Callegan* Lee S. Engel,* James M. Hill,*"f and Richard J. O'Callaghan* Purpose. To compare the chemotherapeutic
More informationEvaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals
J Vet Diagn Invest :164 168 (1998) Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals Susannah K. Hubert, Phouc Dinh Nguyen, Robert D. Walker Abstract.
More informationTel: Fax:
CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.
More information6.0 ANTIBACTERIAL ACTIVITY OF CAROTENOID FROM HALOMONAS SPECIES AGAINST CHOSEN HUMAN BACTERIAL PATHOGENS
6.0 ANTIBACTERIAL ACTIVITY OF CAROTENOID FROM HALOMONAS SPECIES AGAINST CHOSEN HUMAN BACTERIAL PATHOGENS 6.1 INTRODUCTION Microorganisms that cause infectious disease are called pathogenic microbes. Although
More informationRole of Moxifloxacin in Bacterial Keratitis
Original Article Role of Moxifloxacin in Bacterial Keratitis Aamna Jabran, Aurengzeb Sheikh, Syed Ali Haider, Zia-ud-din Shaikh Pak J Ophthalmol 29, Vol. 25 No. 2.................................................................................
More informationPathogens and Antibiotic Sensitivities in Post- Phacoemulsification Endophthalmitis, Kaiser Permanente, California,
Pathogens and Antibiotic Sensitivities in Post- Phacoemulsification Endophthalmitis, Kaiser Permanente, California, 2007-2012 Geraldine R. Slean, MD, MS 1 ; Neal H. Shorstein, MD 2 ; Liyan Liu, MD, MS
More informationTopical Antibiotic Update. Brad Sutton, O.D., F.A.A.O. Indiana University School of Optometry Indianapolis Eye Care Center No financial disclosures
Topical Antibiotic Update Brad Sutton, O.D., F.A.A.O. Indiana University School of Optometry Indianapolis Eye Care Center No financial disclosures What do we have? We currently have many highly effective
More informationStudy of Bacteriological Profile of Corneal Ulcers in Patients Attending VIMS, Ballari, India
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 5 Number 7 (2016) pp. 200-205 Journal homepage: http://www.ijcmas.com Original Research Article http://dx.doi.org/10.20546/ijcmas.2016.507.020
More informationMicrobiology : antimicrobial drugs. Sheet 11. Ali abualhija
Microbiology : antimicrobial drugs Sheet 11 Ali abualhija return to our topic antimicrobial drugs, we have finished major group of antimicrobial drugs which associated with inhibition of protein synthesis
More informationJAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro
Journal of Antimicrobial Chemotherapy (1997) 39, 713 717 JAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro Ian Morrissey* Department of Biosciences, Division of Biochemistry
More informationLab Exercise: Antibiotics- Evaluation using Kirby Bauer method.
Lab Exercise: Antibiotics- Evaluation using Kirby Bauer method. OBJECTIVES 1. Compare the antimicrobial capabilities of different antibiotics. 2. Compare effectiveness of with different types of bacteria.
More informationInternational Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access.
I J A P B International Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access. ISSN: 2454-8375 COMPARISON OF ANTIMICROBIAL ACTIVITY AND MIC OF BRANDED
More informationBurn Infection & Laboratory Diagnosis
Burn Infection & Laboratory Diagnosis Introduction Burns are one the most common forms of trauma. 2 million fires each years 1.2 million people with burn injuries 100000 hospitalization 5000 patients die
More information2 0 hr. 2 hr. 4 hr. 8 hr. 10 hr. 12 hr.14 hr. 16 hr. 18 hr. 20 hr. 22 hr. 24 hr. (time)
Key words I μ μ μ μ μ μ μ μ μ μ μ μ μ μ II Fig. 1. Microdilution plate. The dilution step of the antimicrobial agent is prepared in the -well microplate. Serial twofold dilution were prepared according
More informationChoosing the Ideal Antibiotic Therapy and the Role of the Newer Fluoroquinolones in Respiratory Tract Infections
...CLINICIAN INTERVIEW... Choosing the Ideal Antibiotic Therapy and the Role of the Newer Fluoroquinolones in Respiratory Tract Infections An interview with Robert C. Owens, Jr., PharmD, Clinical Pharmacy
More informationFluoroquinolones resistant Gram-positive cocci isolated from University of Calabar Teaching Hospital, Nigeria
GSC Biological and Pharmaceutical Sciences, 2017, 01(01), 001 005 Available online at GSC Online Press Directory GSC Biological and Pharmaceutical Sciences e-issn: 2581-3250, CODEN (USA): GBPSC2 Journal
More informationDetection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran
Letter to the Editor Detection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran Mohammad Rahbar, PhD; Massoud Hajia, PhD
More informationDebate Series editors: Susan Lightman and Peter McCluskey
1167... Series editors: Susan Lightman and Peter McCluskey Correspondence to: M Daniell, Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, 3065, Australia; daniellm@ozemail.com.au Accepted for
More informationAn Approach to Linezolid and Vancomycin against Methicillin Resistant Staphylococcus Aureus
Article ID: WMC00590 ISSN 2046-1690 An Approach to Linezolid and Vancomycin against Methicillin Resistant Staphylococcus Aureus Author(s):Dr. K P Ranjan, Dr. D R Arora, Dr. Neelima Ranjan Corresponding
More informationChristine E. Thorburn and David I. Edwards*
Journal of Antimicrobial Chemotherapy (2001) 48, 15 22 JAC The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence
More informationDevelopment of Resistant Bacteria Isolated from Dogs with Otitis Externa or Urinary Tract Infections after Exposure to Enrofloxacin In Vitro
A. M. Brothers, P. S. Gibbs, and R. E. Wooley Development of Resistant Bacteria Isolated from Dogs with Otitis Externa or Urinary Tract Infections after Exposure to Enrofloxacin In Vitro Amy M. Brothers,
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationUSA Product Label LINCOCIN. brand of lincomycin hydrochloride tablets. brand of lincomycin hydrochloride injection, USP. For Use in Animals Only
USA Product Label http://www.vetdepot.com PHARMACIA & UPJOHN COMPANY Division of Pfizer Inc. Distributed by PFIZER INC. 235 E. 42ND ST., NEW YORK, NY, 10017 Telephone: 269-833-4000 Fax: 616-833-4077 Customer
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationIntroduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
More informationORIGINAL ARTICLE /j x. Western Reserve University, Cleveland, OH, USA and 3 Wockhardt Research Centre, Aurangabad, India
ORIGINAL ARTICLE 10.1111/j.1469-0691.2004.01017.x Activity of the new quinolone WCK 771 against pneumococci P. C. Appelbaum 1, G. A. Pankuch 1, B. Bozdogan 1, G. Lin 1, M. R. Jacobs 2, M. V. Patel 3, S.
More informationTitle: N-Acetylcysteine (NAC) Mediated Modulation of Bacterial Antibiotic
AAC Accepts, published online ahead of print on June 00 Antimicrob. Agents Chemother. doi:0./aac.0070-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationMICHAEL J. RYBAK,* ELLIE HERSHBERGER, TABITHA MOLDOVAN, AND RICHARD G. GRUCZ
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2000, p. 1062 1066 Vol. 44, No. 4 0066-4804/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. In Vitro Activities of Daptomycin,
More informationANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin
ANTIBIOTICS USED FOR RESISTACE BACTERIA 1. Vancomicin Vancomycin is used to treat infections caused by bacteria. It belongs to the family of medicines called antibiotics. Vancomycin works by killing bacteria
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationTHE STABILITY OF E1VROFLOXA CIN University Undergraduate Research Fellow. A Senior Thesis. Texas ASM University.
THE STABILITY OF E1VROFLOXA CIN A Senior Thesis By Meagan A. Dodge 1997-98 University Undergraduate Research Fellow Texas ASM University Group: Biology THE STABILITY OF ENROFLOXACIN MEAGANA, DODGE Submitted
More informationHelp with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST
Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to
More informationMarc Decramer 3. Respiratory Division, University Hospitals Leuven, Leuven, Belgium
AAC Accepts, published online ahead of print on April 0 Antimicrob. Agents Chemother. doi:./aac.0001- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationPinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu
Search for: Search Search Does levaquin cover anaerobes Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu Levofloxacin, sold under the trade names Levaquin among others, is an antibiotic.
More informationDOSAGE FORMS AND STRENGTHS Otic Suspension: Each OTIPRIO vial contains 1 ml of 6% (60 mg/ml) ciprofloxacin otic suspension. (3)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OTIPRIO safely and effectively. See full prescribing information for OTIPRIO. OTIPRIO (ciprofloxacin
More informationAntibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice?
Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice? With the support of Wallonie-Bruxelles-International 1-1 In vitro evaluation of antibiotics : the antibiogram
More informationZOETIS INC. 333 PORTAGE STREET, KALAMAZOO, MI, Telephone: Customer Service: Website: EXCEDE FOR SWINE
ZOETIS INC. 333 PORTAGE STREET, KALAMAZOO, MI, 49007 Telephone: 269-359-4414 Customer Service: 888-963-8471 Website: www.zoetis.com Every effort has been made to ensure the accuracy of the information
More informationCipro for gram positive cocci in urine
Buscar... Cipro for gram positive cocci in urine 20-6-2017 Pneumonia can be generally defined as an infection of the lung parenchyma, in which consolidation of the affected part and a filling of the alveolar
More informationComparison of Clindamycin, Erythromycin, and Methicillin in Streptococcal Infections in Monkeys
ANTIbMCROBIAL AGENTS AND CHEMOTHERAPY, June 197, p. 460-465 Copyright 197 American Society for Microbiology Vol. 1, No. 6 Printed in U.S.A. Comparison of Clindamycin, Erythromycin, and Methicillin in Streptococcal
More informationANTIMICROBIAL TESTING. with ALKA VITA (ALKAHYDROXY ) ESCHERICHIA COLI STAPHYLOCOCCUS AUREUS (MRSA) PSEUDOMONA AERUGINOSA ENTEROBACTER CLOACAE
ANTIMICROBIAL TESTING with ALKA VITA (ALKAHYDROXY ) on ESCHERICHIA COLI STAPHYLOCOCCUS AUREUS (MRSA) PSEUDOMONA AERUGINOSA ENTEROBACTER CLOACAE FINAL RESULTS OF ANTIBACTERIAL TESTS IN VITRO WITH THE PRODUCT
More informationScottish Medicines Consortium
Scottish Medicines Consortium daptomycin 350mg powder for concentrate for solution for infusion (Cubicin ) Chiron Corporation Limited No. (248/06) 10 March 2006 The Scottish Medicines Consortium (SMC)
More informationORIGINAL ARTICLE. Focus Technologies, Inc., 1 Hilversum, The Netherlands, 2 Herndon, Virginia and 3 Franklin, Tennessee, USA
ORIGINAL ARTICLE In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000 2001 M. E. Jones 1, R. S. Blosser-Middleton
More informationUSA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION
VIRBAC CORPORATION USA Product Label http://www.vetdepot.com P.O. BOX 162059, FORT WORTH, TX, 76161 Telephone: 817-831-5030 Order Desk: 800-338-3659 Fax: 817-831-8327 Website: www.virbacvet.com CLINTABS
More informationPublic Assessment Report. Scientific discussion. Xiflodrop 5 mg/ml eye drops, solution. Moxifloxacin hydrochloride DK/H/2221/001/DC
Public Assessment Report Scientific discussion Xiflodrop 5 mg/ml eye drops, solution Moxifloxacin hydrochloride DK/H/2221/001/DC This module reflects the scientific discussion for the approval of Xiflodrop.
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationRabbit Streptococcus pneumoniae Keratitis Model and Topical Therapy
Rabbit Streptococcus pneumoniae Keratitis Model and Topical Therapy James P. Guzek, 12 Dennis J. Cline 2 Paul K. Row, 5 Izak F. Wessels 2 ' 4 Scott Beeve, 5 Scott Ispirescu, 5 Raydolfo M. Aprecio, 5 James
More informationVOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559. ANTIBIOTIC 6640.* Ill
VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559 ANTIBIOTIC 6640.* Ill BIOLOGICAL STUDIES WITH ANTIBIOTIC 6640, A NEW BROAD-SPECTRUM AMINOGLYCOSIDE ANTIBIOTIC J. Allan Waitz, Eugene L. Moss, Jr., Edwin
More informationBacterial Pathogens in Urinary Tract Infection and Antibiotic Susceptibility Pattern from a Teaching Hospital, Bengaluru, India
ISSN: 2319-7706 Volume 4 Number 11 (2015) pp. 731-736 http://www.ijcmas.com Original Research Article Bacterial Pathogens in Urinary Tract Infection and Antibiotic Susceptibility Pattern from a Teaching
More informationPublic Assessment Report Paediatric data. EXOCIN (OCUFLOX) Ofloxacin. Marketing Autorisation Holder: Allergan
Public Assessment Report Paediatric data EXOCIN (OCUFLOX) Ofloxacin Marketing Autorisation Holder: Allergan Rapporteur: Co-Rapporteur: Currently approved indication(s): Pharmaceutical form(s) and strengths
More informationDiscover the. Discover the. innovative science. Veraflox (pradofloxacin) Veraflox. Efficacy. Safety. Ease-of-use.
Discover the Discover the innovative science. science of Veraflox Oral Veraflox. Suspension for Cats Efficacy. Safety. Ease-of-use. An unprecedented combination of efficacy, safety and ease-of-use. Designed
More informationBacterial Resistance of Respiratory Pathogens. John C. Rotschafer, Pharm.D. University of Minnesota
Bacterial Resistance of Respiratory Pathogens John C. Rotschafer, Pharm.D. University of Minnesota Antibiotic Misuse ~150 million courses of antibiotic prescribed by office based prescribers Estimated
More informationOriginal Article. Suwanna Trakulsomboon, Ph.D., Visanu Thamlikitkul, M.D.
Original Article Vol. 25 No. 2 In vitro activity of daptomycin against MRSA:Trakulsomboon S & Thamlikitkul V. 57 In Vitro Activity of Daptomycin against Methicillin- Resistant Staphylococcus aureus (MRSA)
More informationEffects of Minocycline and Other Antibiotics on Fusobacterium necrophorum Infections in Mice
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1975, p. 421-425 Copyright 0 1975 American Society for Microbiology Vol. 7, No. 4 Printed in U.S.A. Effects of Minocycline and Other s on Fusobacterium necrophorum
More informationSURVIVABILITY OF HIGH RISK, MULTIRESISTANT BACTERIA ON COTTON TREATED WITH COMMERCIALLY AVAILABLE ANTIMICROBIAL AGENTS
SURVIVABILITY OF HIGH RISK, MULTIRESISTANT BACTERIA ON COTTON TREATED WITH COMMERCIALLY AVAILABLE ANTIMICROBIAL AGENTS Adrienn Hanczvikkel 1, András Vígh 2, Ákos Tóth 3,4 1 Óbuda University, Budapest,
More informationClinical Features, Antibiotic Susceptibility Profile, and Outcomes of Infectious Keratitis Caused by Stenotrophomonas maltophilia
Clinical Features, Antibiotic Susceptibility Profile, and Outcomes of Infectious Keratitis Caused by Stenotrophomonas maltophilia Sotiria Palioura, MD, MSc, PhD Cornea & External Disease Specialist Athens
More informationAnnual Report: Table 1. Antimicrobial Susceptibility Results for 2,488 Isolates of S. pneumoniae Collected Nationally, 2005 MIC (µg/ml)
Streptococcus pneumoniae Annual Report: 5 In 5, a total of, isolates of pneumococci were collected from 59 clinical microbiology laboratories across Canada. Of these, 733 (9.5%) were isolated from blood
More informationEXCEDE Sterile Suspension
VIAL LABEL MAIN PANEL PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN READ SAFETY DIRECTIONS FOR ANIMAL TREATMENT ONLY EXCEDE Sterile Suspension 200 mg/ml CEFTIOFUR as Ceftiofur Crystalline Free
More informationAn evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage
Journal of Antimicrobial Chemotherapy (1991) 27, Suppl. C, 1-7 An evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage J. J. Muscato",
More informationIsolation, identification and antimicrobial susceptibility pattern of uropathogens isolated at a tertiary care centre
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 10 (2015) pp. 951-955 http://www.ijcmas.com Original Research Article Isolation, identification and antimicrobial
More informationOriginal Article. Hossein Khalili a*, Rasool Soltani b, Sorrosh Negahban c, Alireza Abdollahi d and Keirollah Gholami e.
Iranian Journal of Pharmaceutical Research (22), (2): 559-563 Received: January 2 Accepted: June 2 Copyright 22 by School of Pharmacy Shaheed Beheshti University of Medical Sciences and Health Services
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimum Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) Broth dilution: cation-adjusted Mueller-Hinton
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE
European Medicines Agency Veterinary Medicines and Inspections EMEA/CVMP/211249/2005-FINAL July 2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE DIHYDROSTREPTOMYCIN (Extrapolation to all ruminants)
More informationDelayed-Onset Post-Keratoplasty Endophthalmitis Caused by Vancomycin-Resistant Enterococcus faecium
This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license), applicable to the online version of the article
More informationIn vitro antibiotic resistance in bacterial keratitis in London
Br J Ophthalmol 2000;84:687 691 687 Moorfields Eye Hospital, London EC1V 2PD SJTuft Institute of Ophthalmology, London EC1V 9QS M Matheson Correspondence to: Mr S J Tuft, Moorfields Eye Hospital, City
More informationJournal of Antimicrobial Chemotherapy Advance Access published August 26, 2006
Journal of Antimicrobial Chemotherapy Advance Access published August, Journal of Antimicrobial Chemotherapy doi:./jac/dkl Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae,
More informationGuidelines for Laboratory Verification of Performance of the FilmArray BCID System
Guidelines for Laboratory Verification of Performance of the FilmArray BCID System Purpose The Clinical Laboratory Improvement Amendments (CLIA), passed in 1988, establishes quality standards for all laboratory
More informationSynergism of penicillin or ampicillin combined with sissomicin or netilmicin against enterococci
Journal of Antimicrobial Chemotherapy (78) 4, 53-543 Synergism of penicillin or ampicillin combined with sissomicin or netilmicin against enterococci Chatrchal Watanakunakoni and Cheryl Glotzbecker Infectious
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrocare 50 mg/ml Solution for Injection for Cattle, Pigs, Dogs and Cats (UK, IE, FR) Floxadil 50 mg/ml Solution for Injection
More informationLEVOFLOXACIN RESIDUES IN CHICKEN MEAT AND GIBLETS
Bulgarian Journal of Veterinary Medicine (2013), 16, Suppl. 1, 216 219 LEVOFLOXACIN RESIDUES IN CHICKEN MEAT AND GIBLETS R. KYUCHUKOVA 1, V. URUMOVA 2, M. LYUTSKANOV 2, V. PETROV 2 & A. PAVLOV 1 1 Department
More informationPharmaceutical Form Ciprofloxacin 2 mg/ml Solution for infusion. Applicant Name Strength. Ciprofloxacin Nycomed. Ciprofloxacin Nycomed
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTE OF ADMINISTRATION, APPLICANT/ MARKETING AUTHORISATION HOLDER IN THE MEMBER STATES Marketing Member State Authorisation
More informationDetection of Methicillin Resistant Strains of Staphylococcus aureus Using Phenotypic and Genotypic Methods in a Tertiary Care Hospital
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 7 (2017) pp. 4008-4014 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.607.415
More informationQ1. (a) Clostridium difficile is a bacterium that is present in the gut of up to 3% of healthy adults and 66% of healthy infants.
Q1. (a) Clostridium difficile is a bacterium that is present in the gut of up to 3% of healthy adults and 66% of healthy infants. C. difficile rarely causes problems, either in healthy adults or in infants.
More informationSELECT NEWS. Florfenicol Monograph: Injectable Therapy for Cattle
SELECT NEWS Florfenicol Monograph: Injectable Therapy for Cattle Did you know that? Florfenicol is one of the most powerful antibiotics currently available in veterinary medicine with one of the lowest
More informationAntibiotic Kinetic and Dynamic Attributes for Community-Acquired Respiratory Tract Infections
...PRESENTATIONS... Antibiotic Kinetic and Dynamic Attributes for Community-Acquired Respiratory Tract Infections David P. Nicolau, PharmD Presentation Summary Factors, including the age of the treatment
More informationBacterial keratitis is a major cause of corneal opacity and loss
Immunology and Microbiology An In Vitro Investigation of Synergy or Antagonism between Antimicrobial Combinations against Isolates from Bacterial Keratitis Henri Sueke, 1,2 Stephen B. Kaye, 1 Timothy Neal,
More informationEXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING
EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING CHN61: EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING 1.1 Introduction A common mechanism of bacterial resistance to beta-lactam antibiotics is the production
More informationEuropean Public MRL assessment report (EPMAR)
18 March 2016 EMA/CVMP/619817/2015 Committee for Medicinal Products for Veterinary Use European Public MRL assessment report (EPMAR) Gentamicin (all mammalian food producing species and fin fish) On 3
More informationEDUCATIONAL COMMENTARY CURRENT METHODS IN ANTIMICROBIAL SUSCEPTIBILITY TESTING
Commentary provided by: Linsey Donner, MPH, CPH, MLS (ASCP) CM Assistant Professor, Microbiology and Serology College of Allied Health Professions, Division of Medical Laboratory Science University of
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationKeywords: amoxicillin/clavulanate, respiratory tract infection, antimicrobial resistance, pharmacokinetics/pharmacodynamics, appropriate prescribing
Journal of Antimicrobial Chemotherapy (2004) 53, Suppl. S1, i3 i20 DOI: 10.1093/jac/dkh050 Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review
More informationChallenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems
Micro 301 Antimicrobial Drugs 11/7/12 Significance of antimicrobial drugs Challenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems Definitions Antibiotic Selective
More informationBurton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents
Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How
More informationAntibiotic Susceptibility of Common Bacterial Pathogens in Canine Urinary Tract Infections
Vol.1 No.2 Oct-Dec 2013 ISSN : 2321-6387 Antibiotic Susceptibility of Common Bacterial Pathogens in Canine Urinary Tract Infections S. Yogeshpriya*, Usha N.Pillai, S. Ajithkumar and N. Madhavan Unny Department
More informationTest Method Modified Association of Analytical Communities Test Method Modified Germicidal Spray Products as Disinfectants
Study Title Antibacterial Activity and Efficacy of E-Mist Innovations' Electrostatic Sprayer Product with Multiple Disinfectants Method Modified Association of Analytical Communities Method 961.02 Modified
More informationNebcin0 in the treatment of experimental
Brit. J. Ophthal. (15) 5, 5 Nebcin in the treatment of experimental Pseudomonas keratitis RUBENS BELFORT, JR., GLBERT SMOLN, MASAO OKUMOTO, and HONG BOK KM From the Francis. Proctor Foundation for Research
More informationEDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update
EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain
More informationBarriers to Intravenous Penicillin Use for Treatment of Nonmeningitis
JCM Accepts, published online ahead of print on 7 July 2010 J. Clin. Microbiol. doi:10.1128/jcm.01012-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationProphylactic antibiotic timing and dosage. Dr. Sanjeev Singh AIMS, Kochi
Prophylactic antibiotic timing and dosage Dr. Sanjeev Singh AIMS, Kochi Meaning - Webster Medical Definition of prophylaxis plural pro phy lax es \-ˈlak-ˌsēz\play : measures designed to preserve health
More informationDynamic Drug Combination Response on Pathogenic Mutations of Staphylococcus aureus
2011 International Conference on Biomedical Engineering and Technology IPCBEE vol.11 (2011) (2011) IACSIT Press, Singapore Dynamic Drug Combination Response on Pathogenic Mutations of Staphylococcus aureus
More information56 Clinical and Laboratory Standards Institute. All rights reserved.
Table 2C 56 Clinical and Laboratory Standards Institute. All rights reserved. Table 2C. Zone Diameter and Minimal Inhibitory Concentration Breakpoints for Testing Conditions Medium: Inoculum: diffusion:
More informationOther β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL
Other β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL David P. Nicolau, PharmD, FCCP, FIDSA Director, Center for Anti-Infective Research and Development Hartford Hospital
More informationOriginal Article. Ratri Hortiwakul, M.Sc.*, Pantip Chayakul, M.D.*, Natnicha Ingviya, B.Sc.**
Original Article In Vitro Activity of Cefminox and Other β-lactam Antibiotics Against Clinical Isolates of Extended- Spectrum-β-lactamase-Producing Klebsiella pneumoniae and Escherichia coli Ratri Hortiwakul,
More informationComparative In Vitro Activity of Prulifloxacin against Bacteria Isolated from Hospitalized Patients at Siriraj Hospital
Original Article Vol. 27 No. 2 In vitro activity of prulifloxacin against clinical bacterial isolates:- Thamlikitkul V & Tiengrim S. 61 Comparative In Vitro Activity of n against Bacteria Isolated from
More informationThe Basics: Using CLSI Antimicrobial Susceptibility Testing Standards
The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More information.'URRENT THERAPEUTIC RESEA. VOLUME 66, NUMBER 3, MAY/JuNE 2005
.'URRENT THERAPEUTIC RESEA VOLUME 66, NUMBER 3, MAY/JuNE 2005 Efficacy of Moxifloxacin Monotherapy Versus Gatifloxacin Monotherapy, Piperacillin- Tazobactam Combination Therapy, and Clindamycin Plus Gentamicin
More information